Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

PIMECROLIMUS for Dermatitis: Side Effects & Safety Data

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

There are 55 adverse event reports in the FDA FAERS database where PIMECROLIMUS was used for Dermatitis.

Most Reported Side Effects for PIMECROLIMUS

Side Effect Reports % Deaths Hosp.
Drug ineffective 349 26.3% 0 16
Treatment failure 139 10.5% 0 0
Psoriasis 114 8.6% 0 9
Off label use 113 8.5% 0 2
Pruritus 94 7.1% 0 4
Erythema 89 6.7% 0 4
Product use in unapproved indication 86 6.5% 1 1
Rash 82 6.2% 0 4
Application site pain 72 5.4% 0 2
Therapeutic product effect incomplete 65 4.9% 0 3
Condition aggravated 59 4.5% 0 5
Drug ineffective for unapproved indication 55 4.1% 0 0
Eczema 52 3.9% 0 5
Skin exfoliation 48 3.6% 0 3
Application site erythema 41 3.1% 0 1

Other Indications for PIMECROLIMUS

Product used for unknown indication (354) Psoriasis (217) Eczema (148) Dermatitis atopic (103) Rash (52) Rosacea (46) Product use in unapproved indication (40) Pruritus (28) Dermatitis contact (20) Vitiligo (20)

Other Drugs Used for Dermatitis

DUPILUMAB (9,959) CRISABOROLE (407) APREMILAST (122) TRALOKINUMAB-LDRM (90) KETOCONAZOLE (66) CYCLOSPORINE (62) DOXYCYCLINE (57) CLOBETASOL (50) RUXOLITINIB (50) TRIAMCINOLONE ACETONIDE (48)

Related Pages

PIMECROLIMUS Full Profile All Dermatitis Drugs PIMECROLIMUS Demographics PIMECROLIMUS Timeline